Device/Diagnostics Quarterly Deal Statistics, Q2 2013

A look at financing, M&A, and alliance activity, April–June 2013

Similar to Q1’s deal dollars and volume, device companies raised $1.06 billion through 45 transactions; Bayer HealthCare’s $1 billion purchase of Conceptus was the only device M&A in Q2 to exceed the billion-dollar mark. Diagnostics players raised a total of $2.9 billion during the second quarter, a huge increase over Q1 due to Thermo Fisher Scientific’s $2.46 billion follow-on offering to support its $15.2 billion April acquisition of Life Technology, another Q2 outlier in the M&A category.

In the second quarter of 2013, device companies raised $1.06 billion (45 transactions), on par with the $1.1 billion amassed in the previous quarter for about the same number of deals. (See Exhibit 1.) Late-stage venture financing again led, bringing in $384 million. Top fundraiser Proteus Digital Health Inc. grossed $63 million in a Series F round from corporate backers Oracle Corp., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and return investor Sino Portfolio. [See Deal] Proteus has brought in $180 million since its 2001 inception and in July 2012 received FDA approval for its ingestible sensor device (see[A#01120806010]), capable of communicating physiologic and behavioral data to caregivers via a wireless signal contained in the sensor. The diagnostic imaging field had a decent showing from three firms completing late-stage raises: a $36 million Series D by SuperSonic Imagine SA (ultrasound) [See Deal], a $25 million Series Cby Topera Medical Inc. (3-D cardio display) [See Deal], and a $17 million Series D from ViewRay Inc. (MRI-guided cancer radiotherapy). [See Deal]

Exhibit 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By 

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy